30 days ago
74 days ago
Yes, I still think that shares in Skinbiotherapeutics (SBTX) are cheap at 19p, that there will be three quarters of revenues from Croda booked in the year to June 30 2025 with two quarters fully paid. But I see that the shares are off a penny today because we know what is looming.
79 days ago
Folks like the Lemming thought that Skinbiotherapeutics (SBTX) FD Manprick Randhawa was the bees knees and were jolly cross with me for rebranding him for his patent incompetence. In my view he was useless, unable to communicate with serious investors or to stop Stuart Ashman abusing the word accretive and, at least, partially responsible for the cack handed and dilutive financing of two acquisitions. He was unable to control costs. Well, today, he has gone to pursue other business interests. Great news.. It has prompted me to buy more shares, increasing my holding by 25%.
80 days ago
In today's podcast I look at Croda (CRDA) and Skinbiotherapeutics (SBTX), V22, Avacta (AVCT), the biggest threat to your wealth and it is not what Gary Newman et al are foaming at the mouth about, at Cleantech Lithium (CTL) and the disgrace at Anexo (ANX)
80 days ago
Croda (CRDA) has a trading statement out today and the Skinbiotherapeutics (SBTX) obsessives are looking at how revenues from consumer care leapt by £18 million, Quarter on Quarter, to £255 million in Q1 2025. Natch they speculate as to how much of this is Skins related, bearing in mind that Skins would get a double digit margin on whatever is sold. I reckon the answer is “norra lot” but such speculation has pushed the shares up to 25.5p. Now here is my guess for the next RNS!
84 days ago
I discuss why the former is not, I believe a threat and why Optibiotix (OPTI) shares are so cheap and on the latter I comment on the idea that Croda (CRDA) might launch a cheeky 50p a share bid for Skinbiotherapeutics (SBTX). FWIW I think its unlikely although stranger things happen at sea.
94 days ago
110 days ago
123 days ago
136 days ago
144 days ago
I start with an observation ( supportive) and a question about Tesco (TSCO). then a few thoughts on why interest rate cuts will not necessarily drive growth. Then Skinbiotherapeutics (SBTX) and its Croda NDA. Finally, prompted by PL, what makes a strong shareholder list?
214 days ago
Skinbiotherapeutics (SBTX) is very simple. If you believe that Croda could deliver £25 million GP or anywhere close to that as CEO Stuart Ashman has intimated the shares are stupendously cheap at 17.75p. Ashman needs to do nothing apart from deliver other corporate deals and more GP from his existing IP and no more shares need be issued. Hell’s teeth why issue shares now or indeed at twice or three times the price given that on Ashman’s Croda numbers the shares could easily be 100p or even 200p! But Ashman is a git.
223 days ago
I wonder why shares in SkinBiotherapeutics (SBTX) have not raced ahead more on the news from Croda. One possible explanation put to me by Lemming investor is that Optibiotix (OPTI) has been reducing its holding which was last stated at 10.92%.
779 days ago
SkinBioTherapeutics (SBTX) has announced on its AxisBiotix-Ps (psoriasis) product that it has commenced sales in Spain aided by the launch of a regional website and on its skin care active ingredient SkinBiotix that partner, cosmetics business of FTSE-100 Croda (CRDA), Sederma has noted ‘exciting’ additional benefits which means delays in monetisation. Is that good news or bad?
1420 days ago
SkinBioTherapeutics (SBTX) has delivered a “Business Update” including that the commercial launch of AxisBiotix-Ps is on track for Q4 and has further encouraging potential, that SkinBiotix manufacturing scale-up with Croda (CRDA) is progressing to schedule and 30th June year-end cash totalled £4.6 million. Sounds good.